Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.25), $0.94 better than the analyst estimate of ($4.19). Revenue for the quarter came in at $311.34 million versus the consensus estimate of $301.29 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.